Kintara Therapeutics Inc (KTRA): They cancelled offering

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	15
Posts	2140
Boards Moderated	0
Alias Born	04/05/2017

Pt3

Re: None

Thursday, 03/14/2024 3:07:24 AM

Thursday, March 14, 2024 3:07:24 AM

They cancelled offering

Keep Last Read

Replies (2) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent KTRA News

Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/17/2024 08:10:11 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/17/2024 08:05:37 PM
Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 05/14/2024 08:55:04 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:50:14 PM
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results • PR Newswire (US) • 05/14/2024 08:45:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:40:36 PM
Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 05/13/2024 08:06:50 PM
Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm • PR Newswire (US) • 04/05/2024 05:09:00 PM
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement • PR Newswire (US) • 04/03/2024 11:00:00 AM
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab • PR Newswire (US) • 03/27/2024 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:59:49 AM
Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:00:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:00:10 PM
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:07:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 02:05:27 PM
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer • PR Newswire (US) • 02/12/2024 02:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:10:10 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/18/2023 09:05:21 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:15:08 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 02:10:19 PM
Kintara Therapeutics Announces Review of Strategic Alternatives • PR Newswire (US) • 12/07/2023 02:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 02:10:08 PM
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement • PR Newswire (US) • 12/05/2023 02:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2023 12:55:37 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:15:23 PM

More KTRA News

InvestorsHub NewsWire

North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM

Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM

Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM

VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM

ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM

Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover